JT Stratford LLC Grows Holdings in Pfizer Inc. $PFE

JT Stratford LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 301.6% in the third quarter, Holdings Channel reports. The firm owned 70,370 shares of the biopharmaceutical company’s stock after buying an additional 52,849 shares during the quarter. JT Stratford LLC’s holdings in Pfizer were worth $1,793,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of PFE. Fiduciary Alliance LLC raised its position in Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after buying an additional 46,043 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Pfizer during the third quarter worth about $3,019,000. Money Concepts Capital Corp increased its stake in shares of Pfizer by 29.9% during the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after acquiring an additional 57,188 shares during the period. Vista Investment Partners LLC raised its holdings in Pfizer by 236.1% during the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock worth $1,774,000 after purchasing an additional 48,900 shares in the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. lifted its position in Pfizer by 76.4% in the third quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock valued at $2,784,000 after purchasing an additional 47,319 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the topic of several recent analyst reports. Citigroup assumed coverage on Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price on the stock. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 price target on shares of Pfizer in a research note on Wednesday, November 5th. Finally, Daiwa Securities Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research note on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $28.05.

Pfizer Stock Up 0.1%

PFE stock opened at $26.61 on Thursday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The company’s 50 day simple moving average is $26.23 and its 200-day simple moving average is $25.45. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The firm has a market capitalization of $151.31 billion, a PE ratio of 19.57 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.5%. Pfizer’s payout ratio is presently 126.47%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Argus raised Pfizer to a “Buy,” giving the stock near‑term analyst momentum that can attract flows. Pfizer (NYSE:PFE) Raised to “Buy” at Argus
• Positive Sentiment: Pfizer reported progress on PF‑07328948 (kidney function) Phase 1 work — a pipeline advancement that supports longer‑term product value and upside beyond current franchises. Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value
• Positive Sentiment: Oncology milestones (PADCEV+Keytruda Phase 3 benefits and full FDA approval for a BRAFTOVI regimen) reshape growth prospects away from COVID‑era revenues — a material strategic positive for future revenue mix. Pfizer Oncology Milestones Reshape Outlook Beyond COVID 19 Revenues
• Positive Sentiment: Telescope Innovations installed a second self‑driving lab at Pfizer — a tangible move toward Physical AI and factory automation that could improve throughput, quality, and costs over time. Telescope Innovations Installs Second Self-Driving Lab at Pfizer, Advancing Physical AI Deployment
• Positive Sentiment: Market commentary continues to frame Pfizer as a defensive, high‑yield option (dividend yield cited as attractive), which supports demand in risk‑off environments. The Dividend Safe Harbor: 2 Stocks to Watch (PFE)
• Positive Sentiment: Analyst/market pieces highlight improving cash generation and active portfolio renewal, reinforcing a recovery narrative that could boost multiple expansion if sustained. Pfizer’s Quiet Cash Comeback Pfizer’s Portfolio Renewal In Progress – High Yields For The Patient
• Neutral Sentiment: Consensus analyst rating remains a “Hold” per a recent roundup — a signal that while sentiment is improving, broad analyst conviction is not yet uniformly bullish. Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of “Hold” from Analysts
• Neutral Sentiment: Industry reports on AI in pharma manufacturing note Pfizer among large firms integrating AI — a positive trend but more structural and longer‑term than an immediate earnings driver. AI in Pharma Manufacturing Market Research 2026-2040
• Neutral Sentiment: NYSE floor events (bell‑ringing notices) are routine market color without company‑specific impact. NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.